恒瑞医药：HR091506片上市许可申请获国家药监局受理

Core Viewpoint - Heng Rui Medicine (600276.SH) has received acceptance from the National Medical Products Administration for its HR091506 tablet, aimed at long-term treatment of hyperuricemia in gout patients [1] Group 1: Product Development - HR091506 is a self-developed oral sustained-release tablet utilizing gastric retention technology, featuring pulse release characteristics [1] - The product consists of a rapid-release portion that quickly achieves effective blood drug concentration and a delayed-release portion that maintains drug concentration over time [1] - The total R&D investment for the HR091506 project has reached approximately 126.7 million yuan (unaudited) [1]